Latest News
BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?
BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that...
Latest News
In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows
In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...
Cresset’s Flare AI Client Turns Hours of Work into Minutes
Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...
The National Priority Voucher: Inside the FDA’s Shortest Review Pathway
Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
ADHD Management for the Entire Active Day is Within Reach
When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Weekly News Roundup | 31 August 2026
Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...
Terpenes and Cytokine Modulation: The Evidence Gap in Clinical Aromatherapy
Inflammation is one of the most extensively studied biological processes in modern health science—and one of the most misunderstood concepts in clinical aromatherapy, natural-products and beauty. Inflammation is not inherently harmful. It is a coordinated biological...
Creative Biolabs’ CRISPR Cell Line Development: Plan the Validation First
CRISPR has expanded the possibilities for creating genetically defined cell models, from loss-of-function knockouts to precise knock-ins and stable Cas9-expressing systems. However, successful CRISPR cell line development depends on more than editing efficiency. The...
Autogene Cevumeran Halt Redraws Cancer Vaccine Trial Design
BioNTech and Genentech have stopped a Phase 2 trial of autogene cevumeran in colorectal cancer. An independent data safety monitoring board recommended the termination. The companies confirmed the decision on 28 August 2026. It arrives nine days after a landmark...
Brepocitinib Dermatomyositis Approval Breaks the Steroid-First Pattern
The brepocitinib dermatomyositis approval landed on 27 August 2026. It is the first shift in a treatment field that has barely moved in decades. The US Food and Drug Administration cleared LISRAYA, an oral dual TYK2 and JAK1 inhibitor, for adults with dermatomyositis....
Why Preventive Foot Care Should Be Central to Diabetes Management
Podiatric input is still mostly reactive, despite the significant advancements in diabetes care in recent decades. All too frequently, patients are referred to podiatry only after infections or ulcers have already occurred. This reactive approach is expensive in terms...
Clinical Trials Roundup | 28 Aug 2026
Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...
From EHR Data to Real-World Evidence: Health IT Meets R&D
For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...
Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer
The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...
When Meditation Meets the Page: Can Writing Help Us Understand the Mind?
Meditation may help us observe an experience without immediately reacting to it. Expressive writing may help us give that experience language, structure and meaning. What happens when we stop trying to escape an uncomfortable thought or emotion and instead observe it...
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
ADHD Management for the Entire Active Day is Within Reach
When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Weekly News Roundup | 31 August 2026
Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...
Terpenes and Cytokine Modulation: The Evidence Gap in Clinical Aromatherapy
Inflammation is one of the most extensively studied biological processes in modern health science—and one of the most misunderstood concepts in clinical aromatherapy, natural-products and beauty. Inflammation is not inherently harmful. It is a coordinated biological...
Creative Biolabs’ CRISPR Cell Line Development: Plan the Validation First
CRISPR has expanded the possibilities for creating genetically defined cell models, from loss-of-function knockouts to precise knock-ins and stable Cas9-expressing systems. However, successful CRISPR cell line development depends on more than editing efficiency. The...
Autogene Cevumeran Halt Redraws Cancer Vaccine Trial Design
BioNTech and Genentech have stopped a Phase 2 trial of autogene cevumeran in colorectal cancer. An independent data safety monitoring board recommended the termination. The companies confirmed the decision on 28 August 2026. It arrives nine days after a landmark...
Brepocitinib Dermatomyositis Approval Breaks the Steroid-First Pattern
The brepocitinib dermatomyositis approval landed on 27 August 2026. It is the first shift in a treatment field that has barely moved in decades. The US Food and Drug Administration cleared LISRAYA, an oral dual TYK2 and JAK1 inhibitor, for adults with dermatomyositis....
Why Preventive Foot Care Should Be Central to Diabetes Management
Podiatric input is still mostly reactive, despite the significant advancements in diabetes care in recent decades. All too frequently, patients are referred to podiatry only after infections or ulcers have already occurred. This reactive approach is expensive in terms...
Clinical Trials Roundup | 28 Aug 2026
Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...
From EHR Data to Real-World Evidence: Health IT Meets R&D
For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...
Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer
The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...
When Meditation Meets the Page: Can Writing Help Us Understand the Mind?
Meditation may help us observe an experience without immediately reacting to it. Expressive writing may help us give that experience language, structure and meaning. What happens when we stop trying to escape an uncomfortable thought or emotion and instead observe it...
Featured Articles
Further News
Oral GLP-1 Manufacturing: Can Supply Meet Demand?
Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...
Zanidatamab Approval Resets First-Line HER2 Gastric Cancer Care
The US Food and Drug Administration cleared two zanidatamab regimens on 25 August 2026. The zanidatamab approval covers first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma. It displaces trastuzumab from a first-line backbone that has...
Leverage Trauma-Informed Care to Enhance Adherence to Safety Interventions
Patient trauma can have a significant impact on the ways in which patients interact with the healthcare environment and with its staff. Many patient behaviors can stem from trauma, including lack of adherence to care plans. In the context of patient safety,...
Robotic Gastrectomy Outperforms Laparoscopic Surgery in Japanese Study
Robotic gastrectomy delivers measurably better perioperative outcomes than conventional laparoscopic surgery for gastric cancer, according to a nationwide analysis of Japanese surgical practice covering more than 22,000 patients. Gastric cancer is the fifth most...
Roche Backs Lean Mass Preservation With $2.3bn Hanmi Obesity Deal
Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...
How Sustainability Can Become a Competitive Advantage in Biomanufacturing
Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...
Obesity Drug News: GLP-1 Readouts and Approval Watch
Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease
The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Why Ingredient Research Is Only the Beginning of a Health Product
I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...
Weekly News Roundup | 24 August 2026
Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.